Wang Hou-cai, Li Wen-qian, Feng Jian-ming
Department of Hematology, Medical College of Qinghai University, Xining, China.
Zhonghua Nei Ke Za Zhi. 2011 Sep;50(9):763-5.
To explore the clinical significance of immunocyte subsets before and after immunosuppressive therapy in the peripheral blood of patients with immune thrombocytopenic purpura (ITP).
The percentages of immunocyte subsets in the peripheral blood of 35 patients with ITP and 20 healthy controls were detected by flow cytometry, including CD(3)(+), CD(4)(+), CD(8)(+), CD(+)(56), CD(19)(+) lymphocytes and CD(4)(+)/CD(8)(+).
The percentages of CD(3)(+) T lymphocyte (61.58 ± 6.45)%, CD(4)(+) T lymphocyte (28.38 ± 4.89)% and the ratio of CD(4)(+)/CD(8)(+) 0.99 ± 0.22 in patients with ITP were lower than those in healthy controls [(67.85 ± 4.68)%, (38.00 ± 3.37)%, 1.54 ± 0.13, all P < 0.05]. After immunosuppressive therapy, the percentages of CD(3)(+)T lymphocyte (69.41 ± 5.03)%, CD(4)(+)T lymphocyte (38.17 ± 3.18)% and the ratio of CD(4)(+)/CD(8)(+) 1.60 ± 0.15 recovered to control levels. The percentages of CD(8)(+)T lymphocyte (29.20 ± 4.50)% and CD(19)(+)B lymphocyte (17.74 ± 4.14)% were higher than those in healthy controls [(24.82 ± 2.93)% and (12.09 ± 3.51)%, all P < 0.05]. After the immunosuppressive therapy, the percentages of CD(8)(+)T lymphocyte (24.06 ± 3.02)% and CD(19)(+)B lymphocyte (10.90 ± 3.55)% recovered to control levels. There were no significant difference of the percentage of CD(56)(+) lymphocyte among ITP patients (15.80 ± 2.85)%, ITP patients after immunosuppressive therapy (15.16 ± 2.77)% and healthy controls (16.36 ± 2.75)%.
The aberrant immunocyte subsets are involved in the pathogenesis of ITP, and detection of immunocyte subsets might be helpful for the diagnosis and determination of therapeutic outcome of ITP.
探讨免疫性血小板减少性紫癜（ITP）患者外周血免疫细胞亚群在免疫抑制治疗前后的临床意义。
采用流式细胞术检测35例ITP患者和20例健康对照者外周血免疫细胞亚群的百分比，包括CD(3)(+)、CD(4)(+)、CD(8)(+)、CD(+)(56)、CD(19)(+)淋巴细胞及CD(4)(+)/CD(8)(+)。
ITP患者CD(3)(+)T淋巴细胞百分比（61.58±6.45）%、CD(4)(+)T淋巴细胞百分比（28.38±4.89）%及CD(4)(+)/CD(8)(+)比值0.99±0.22均低于健康对照者[（67.85±4.68）%、（38.00±3.37）%、1.54±0.13，P均<0.05]。免疫抑制治疗后，CD(3)(+)T淋巴细胞百分比（69.41±5.03）%、CD(4)(+)T淋巴细胞百分比（38.17±3.18）%及CD(4)(+)/CD(8)(+)比值1.60±0.15恢复至对照水平。ITP患者CD(8)(+)T淋巴细胞百分比（29.20±4.50）%和CD(19)(+)B淋巴细胞百分比（17.74±4.14）%高于健康对照者[（24.82±2.93）%和（12.09±3.51）%，P均<0.05]。免疫抑制治疗后，CD(8)(+)T淋巴细胞百分比（24.06±3.02）%和CD(19)(+)B淋巴细胞百分比（10.90±3.55）%恢复至对照水平。ITP患者、免疫抑制治疗后的ITP患者及健康对照者的CD(56)(+)淋巴细胞百分比比较，差异无统计学意义[分别为（15.80±2.85）%、（15.16±2.77）%、（16.36±2.75）%]。
免疫细胞亚群异常参与ITP的发病机制，检测免疫细胞亚群可能有助于ITP的诊断及判断治疗效果。
Zotero 插件